These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Protective immunization against Enterohemorrhagic Escherichia coli and Shigella dysenteriae Type 1 by chitosan nanoparticle loaded with recombinant chimeric antigens comprising EIT and STX1B-IpaD. Mosadegh S, Abtahi H, Amani J, Karizi SZ, Salmanian AH. Microb Pathog; 2023 Nov 21; 184():106344. PubMed ID: 37704060 [Abstract] [Full Text] [Related]
8. Assembly, Biochemical Characterization, Immunogenicity, Adjuvanticity, and Efficacy of Shigella Artificial Invaplex. Turbyfill KR, Clarkson KA, Vortherms AR, Oaks EV, Kaminski RW. mSphere; 2018 Nov 21; 3(2):. PubMed ID: 29600284 [Abstract] [Full Text] [Related]
9. Molecular cloning and biologically active production of IpaD N-terminal region. Hesaraki M, Saadati M, Honari H, Olad G, Heiat M, Malaei F, Ranjbar R. Biologicals; 2013 Jul 21; 41(4):269-74. PubMed ID: 23731655 [Abstract] [Full Text] [Related]
11. Mapping the functional B-cell epitopes of Shigella invasion plasmid antigen D (IpaD). Li S, Zhang W. Appl Environ Microbiol; 2024 Aug 21; 90(8):e0098824. PubMed ID: 39082807 [Abstract] [Full Text] [Related]
12. Characterization of a multicomponent live, attenuated Shigella flexneri vaccine. DeLaine BC, Wu T, Grassel CL, Shimanovich A, Pasetti MF, Levine MM, Barry EM. Pathog Dis; 2016 Jul 21; 74(5):. PubMed ID: 27106253 [Abstract] [Full Text] [Related]
13. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV. Vaccine; 2011 Sep 16; 29(40):7009-19. PubMed ID: 21787825 [Abstract] [Full Text] [Related]
14. SipD and IpaD induce a cross-protection against Shigella and Salmonella infections. Jneid B, Rouaix A, Féraudet-Tarisse C, Simon S. PLoS Negl Trop Dis; 2020 May 16; 14(5):e0008326. PubMed ID: 32463817 [Abstract] [Full Text] [Related]
17. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Van De Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL, Taylor DN, Hartman AB. Vaccine; 1996 Aug 16; 14(11):1062-8. PubMed ID: 8879103 [Abstract] [Full Text] [Related]
18. Immunogenic Potency of a Chimeric Protein Comprising InvH and IpaD against Salmonella and Shigella spp. Emami Mahmoudabadi FS, Vakili A, Nazarian S, Amani J, Mousavi Gargari SL. Iran J Allergy Asthma Immunol; 2021 Aug 07; 20(4):484-493. PubMed ID: 34418902 [Abstract] [Full Text] [Related]
19. Immunogenicity and protective efficacy offered by a ribosomal-based vaccine from Shigella flexneri 2a. Shim DH, Chang SY, Park SM, Jang H, Carbis R, Czerkinsky C, Uematsu S, Akira S, Kweon MN. Vaccine; 2007 Jun 15; 25(25):4828-36. PubMed ID: 17507120 [Abstract] [Full Text] [Related]